Last reviewed · How we verify
Rituximab, Methotrexate, Temozolomide
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and Temozolomide is an alkylating agent that cross-links DNA.
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and Temozolomide is an alkylating agent that cross-links DNA. Used for Non-Hodgkin's lymphoma, Rheumatoid arthritis, Glioblastoma multiforme.
At a glance
| Generic name | Rituximab, Methotrexate, Temozolomide |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Monoclonal antibody, Antimetabolite, Alkylating agent |
| Target | CD20, Dihydrofolate reductase, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion. Methotrexate inhibits dihydrofolate reductase, which is necessary for DNA synthesis and cell division. Temozolomide alkylates DNA, causing cross-links that prevent DNA replication and transcription.
Approved indications
- Non-Hodgkin's lymphoma
- Rheumatoid arthritis
- Glioblastoma multiforme
Common side effects
- Infusion-related reactions
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
- Infection
Key clinical trials
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (PHASE2)
- Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (PHASE1)
- A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort) (PHASE2)
- Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (PHASE1)
- Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (PHASE2)
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) (PHASE2)
- Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma (PHASE2)
- Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: